Dapagliflozin vs Nivolumab

Dapagliflozin vs Nivolumab: Overview

This comparison examines the pharmacological differences between Dapagliflozin and Nivolumab.

Mechanism of Action

Dapagliflozin: Selective SGLT2 inhibitor reducing renal glucose and sodium reabsorption.

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Dapagliflozin — 12.9 hours; Nivolumab — 27 days.

Chemical Properties

Molecular Formula: Dapagliflozin — C21H25ClO6.

Molecular Weight: Dapagliflozin — 408.8730 g/mol.

Type: Dapagliflozin — Small molecule; Nivolumab — Antibody.